Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2011

View Archived Issues

First-in-human data suggest safety of LY-2090314 in patients with advanced solid tumors

KIST researchers prepare new protein kinase inhibitors

Novel anticancer macrocyclic lactones presented

New antagonists of dopamine D2 receptor and serotonin 5-HT7 receptor claimed

Merck Frosst presents new renin inhibitors

Allergy Therapeutics receives complete report from PEI on MAA for Pollinex Quattro/Complete

Secukinumab reduces symptoms of active rheumatoid arthritis in clinical settings

MLN-4924 has effects in acute myeloid leukemia and high-grade myelodysplastic syndrome

Pasireotide reduces elevated urinary free cortisol in patients with Cushing's disease

Novel serum stroke biomarkers investigated

Albany Molecular Research and Merck & Co. disclose new agents for HIV

Preliminary phase IIa data announced on EPI-A0001 in Friedreich's ataxia

FDA approves Abbott's infant-specific Creon dose

New company BliNK Therapeutics to develop monoclonal antibodies

Vertex and Alios BioPharma enter into agreement for nucleotide drug candidates

Phase I trial of therapeutic anticancer vaccine OCV-105 begins in Japan

FDA grants orphan drug status to Neo-Urinary Conduit

LY-2624803 improves aspects of chronic insomnia in phase II trial

Adolor enters agreement to reacquire full rights to alvimopan hydrate from GSK

Scripps Research Institute receives NIH grant for addiction research

FDA extends PDUFA target date for review of Exparel NDA

Lundbeck completes final trial of phase III nalmefene program in alcohol dependence

JDFR and Selecta Biosciences collaborate on vaccines for type 1 diabetes

Bayer HealthCare submits IND application for BAY-94-9343

CytRx reports encouraging preliminary data from phase II ENABLE trial of bafetinib in B-CLL

Antisense Therapeutics clear to begin phase I ATL-1103 trial in Australia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...